RxDoctor Payments Data

Aileen Baino

Family · Yonkers, NYNPI 1144986910

Payments from drug & device makers

$1,276in general payments, 2019–2025

Across 37 payments — averaging $34.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$428
  • AstraZeneca$169
  • Lexicon Pharmaceuticals, Inc.$150
  • Boehringer Ingelheim$101
  • Pfizer$100
  • Johnson & Johnson$75
  • plus $253 from 6 others

What the payments were for

  • Food & beverage$1,276100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,276 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$26,663
Medicare patients
163
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$182,039
EntrestoSacubitril/Valsartan53$75,032
JardianceEmpagliflozin29$37,884
Repatha SureclickEvolocumab37$36,147
Praluent PenAlirocumab13$14,977
FarxigaDapagliflozin Propanediol13$13,520
XareltoRivaroxaban12$13,154
VascepaIcosapent Ethyl20$11,118
Ranolazine ErRanolazine86$10,474
Nebivolol Hcl63$7,186
Metoprolol Succinate280$4,726
Candesartan Cilexetil66$3,000
Rosuvastatin Calcium121$2,880
Atorvastatin Calcium212$2,086
Ezetimibe57$1,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$100$182,039157 claims
Boehringer IngelheimJardiance$101$37,88429 claims
AstraZenecaFarxiga$169$13,52013 claims
Johnson & JohnsonXarelto$75$13,15412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →